Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of SHR-8068 + adebrelimab + platinum chemotherapy versus tislelizumab + platinum chemotherapy as first-line treatment for PD-L1-negative advanced or metastatic non-small cell lung cancer
CTR20253624Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CS1002 in non-small cell lung cancer (NSCLC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Oct 2025; status: active.
02
Drugs
CS1002
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253624.